News Room


Adcock Ingram Critical Care completes precautionary COVID-19 testing of primary contact employees

2020/04/28 08:38:13

26 April 2020           

Adcock Ingram Critical Care completes precautionary COVID-19 testing of primary contact employees

Midrand – On Thursday, 23 April, an employee at the Aeroton facility tested positive for COVID-19, and as a precaution, 57 employees from a specific operating department were referred to a private pathology laboratory for testing on the same day, and were self-quarantined based on the primary contact trace in line with the company’s COVID-19 protocols. The infected employee is currently in self-isolation.  The Company received the test results from the laboratory on Friday, 24 April 2020, and we are pleased to confirm that all 57 employees who were tested as a precautionary measure based on the primary contact trace at the Critical Care manufacturing facility have tested negative for COVID-19.

The Aeroton plant is temporarily shut down and a deep-clean of the plant is being conducted by a third-party specialist. The facility which produces life-saving products including intravenous drips and blood bags will be closed for the entire long weekend to ensure the deep-clean is conducted properly.

On Friday, 24 April 2020, the inspectorate of the Department of Labour conducted an inspection at the facility.  The Critical Care dedicated COVID-19 executive team engaged with the inspectorate and all already established protocols to support workplace hygiene/employee safety seemed to stand the thorough appraisal.  Employees who are able to do so, will return to work on Tuesday, 28 April 2020 when the factory plans to re-open.

The facility will continue with its established and stringent hygiene protocols, temperature scanning and screening procedures for all staff and visitors, increased sanitisation and use of personal protection equipment, as well as social distancing protocols.

Each Adcock Ingram site (manufacturing and distribution) has a business continuity plan in place detailing all necessary plans and protocols that will be followed should any employee or contractor be suspected of having contracted COVID-19, or tested positive for the virus. The structure of Adcock Ingram’s value chain also means that should any manufacturing facility be temporarily shut down; sufficient stock is available to continue supply to our customers over this period. In the event of one of our distribution centres being closed temporarily, stock can be sourced from other warehouses in the network.

Adcock Ingram has a COVID-19 Crisis response committee that oversees all the initiatives mandated in managing COVID-19 and the related regulations, and ensures that we respond proactively, in a well-considered, responsible and agile manner.

Notes to the Editor


About Adcock Ingram


Adcock Ingram is a leading South African pharmaceutical manufacturer, founded in 1891, and listed on the Johannesburg Stock Exchange. Adcock Ingram manufactures, markets and distributes a wide range of healthcare products. The Company is a leading supplier to both the private and public sectors in South Africa. As a leading healthcare provider, the Company’s mission is to provide quality products that improve the health and lives of the people in the markets we serve.


Media Contact:

Kavitha Singh

Adcock Ingram Healthcare (Pty) Ltd

Tel:         + 27 11 635 0189

Mobile:    +79 566 9527